Clinical Trial Update: An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha [Phase 2]

View source ↗

Summary

Phase 2 extension study evaluating efficacy and safety of STI571 in chronic myeloid leukemia patients refractory to or intolerant of interferon-alpha.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• STI571 (imatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase 2 | Status: COMPLETED | Results posted: 2021-07-22